

PFIZER INC  
Form 8-K  
March 06, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of report (Date of earliest event reported): March 4, 2019**

**PFIZER INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**1-3619**  
**(Commission**  
  
**File Number)**

**13-5315170**  
**(I.R.S. Employer**  
  
**Identification No.)**

235 East 42nd Street

New York, New York  
(Address of principal executive offices)

10017  
(Zip Code)

Registrant's telephone number, including area code: (212) 733-2323

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

### Item 8.01 Other Events

On March 4, 2019, Pfizer Inc. (the Company) priced a public offering of \$500,000,000 aggregate principal amount of 2.800% Notes due 2022, \$750,000,000 aggregate principal amount of 2.950% Notes due 2024, \$1,750,000,000 aggregate principal amount of 3.450% Notes due 2029, \$750,000,000 aggregate principal amount of 3.900% Notes due 2039 and \$1,250,000,000 aggregate principal amount of 4.000% Notes due 2049 (together, the Notes).

The offering of the Notes was made pursuant to the Company's shelf registration statement on Form S-3 (Registration No. 333-223221) filed with the Securities and Exchange Commission on February 26, 2018.

In connection with the offering of the Notes, the Company entered into an underwriting agreement (the Underwriting Agreement) and related pricing agreement (the Pricing Agreement), each dated March 4, 2019, with Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein. The closing of the offering of the Notes is expected to occur on March 11, 2019, subject to the satisfaction of customary closing conditions.

The Underwriting Agreement, the Pricing Agreement and the press release related to the offering are filed as exhibits to this Form 8-K and are incorporated herein by reference.

### Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Exhibit Description
1.1	<u>Underwriting Agreement, dated March 4, 2019.</u>
1.2	<u>Pricing Agreement, dated March 4, 2019.</u>
99.1	<u>Press Release of Pfizer Inc., dated March 4, 2019.</u>

EXHIBIT INDEX

Exhibit No.	Exhibit Description
1.1	<u>Underwriting Agreement, dated March 4, 2019.</u>
1.2	<u>Pricing Agreement, dated March 4, 2019.</u>
99.1	<u>Press Release of Pfizer Inc., dated March 4, 2019.</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

By: /s/ Margaret M. Madden  
Margaret M. Madden  
Senior Vice President and Corporate  
Secretary  
Chief Governance Counsel

Dated: March 6, 2019